Opko Health, Inc 8-K, filed Jul 21, 2020
Opko Health, Inc. (OPK)
8-K
2020-07-21
For: 2020-07-20
View Original
Added on
April 06, 2026
About this 8-K
Opko Health, Inc filed this 8-K on July 21, 2020, reporting on events of July 20, 2020.
Items reported
- Item 7.01: Regulation FD disclosure
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 20, 2020
(Exact Name of Registrant as Specified in its Charter)
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||
(Address of Principal Executive Offices) | (Zip Code) | |||
Registrant’s telephone number, including area code: (305 ) 575-4100
Not Applicable |
Former name or former address, if changed since last report |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
ITEM 7.01. | Regulation FD Disclosure. | |
On July 20, 2020, Jon R. Cohen, M.D., Executive Chairman of BioReference Laboratories, Inc. (“BioReference”), a subsidiary of OPKO Health, Inc. (the “Company”), publicly announced as a guest on the CNBC program, “Mad Money”, that BioReference had reached an agreement in principle with the National Football League (the “NFL”) to provide COVID-19 testing for the NFL. The foregoing agreement in principle with the NFL remains subject to definitive documentation and the parties’ execution and delivery thereof.
The information contained in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
OPKO Health, Inc. | |||
By: | /s/ Steven D. Rubin | ||
Date: July 21, 2020 | Name: | Steven D. Rubin | |
Title: | Executive Vice President - Administration | ||